Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

General Information

Summary This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.
Description All subjects who received BRT-DA01 transplantation in Study MSK-DA01-101 (ie, parent study) will be asked to enroll in Study BRT-DA01-501. Subjects enrolled in this study are to be monitored for safety and clinical outcomes through 5 years post-BRT-DA01 transplantation. For individual participating subjects, the Baseline visit for the BRT-DA01-501 study will be defined as the last observation recorded in the parent study.
Clinical trials phase Long term follow up
Start date (estimated) 2023-05-16
End date (estimated) 2027-09-30
Clinical feature
Label Parkinson's disease
Description A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT05897957
ICTRP weblink
Other study identifiers
Name BRT-DA01-501
Source weblink
Public contact
Sponsors BlueRock Therapeutics


Which differentiated cell type is used
Label dopaminergic neuron
Description A neuron that releases dopamine as a neurotransmitter.


Recruitment Status Enrolling by invitation
Estimated number of participants 12